Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

BACKGROUND AND OBJECTIVES: In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin J Am Soc Nephrol
Auteurs principaux: Edwards, Marie E., Chebib, Fouad T., Irazabal, Maria V., Ofstie, Troy G., Bungum, Lisa A., Metzger, Andrew J., Senum, Sarah R., Hogan, Marie C., El-Zoghby, Ziad M., Kline, Timothy L., Harris, Peter C., Czerwiec, Frank S., Torres, Vicente E.
Format: Artigo
Langue:Inglês
Publié: American Society of Nephrology 2018
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6086720/
https://ncbi.nlm.nih.gov/pubmed/30026287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.01520218
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires